Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gefitinib

FDA-approved product (tablet, oral), marketed as Gefitinib, Iressa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gefitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gefitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gefitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

    NCT00030524 · start 2002-01

    Registered record
    Registry ID
    NCT00030524
    Conditions
    Colorectal Cancer
    Interventions
    gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-01
    Completion
    2003-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventiongefitinib
    PhasePhase 2
    Registry statusCompleted

  • ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

    NCT00026364 · start 2001-11

    Registered record
    Registry ID
    NCT00026364
    Conditions
    Colorectal Cancer
    Interventions
    fluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-11
    Completion
    Not recorded
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionfluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calcium
    PhasePhase 1
    Registry statusCompleted

  • Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

    NCT00025350 · start 2001-10

    Registered record
    Registry ID
    NCT00025350
    Conditions
    Colorectal Cancer
    Interventions
    gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-10
    Completion
    2006-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventiongefitinib
    PhasePhase 2
    Registry statusCompleted

  • Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

    NCT00024089 · start 2001-07

    Registered record
    Registry ID
    NCT00024089
    Conditions
    Head and Neck Cancer
    Interventions
    gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    Interventiongefitinib
    PhasePhase 2
    Registry statusCompleted

  • ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

    NCT00006049 · start 2000-05

    Registered record
    Registry ID
    NCT00006049
    Conditions
    Lung Cancer
    Interventions
    carboplatin; gefitinib; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2000-05
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventioncarboplatin; gefitinib; paclitaxel
    PhasePhase 3
    Registry statusUnknown